| http://www.w3.org/ns/prov#value | - ted history of operations; our losses since inception and for the foreseeable future; our lack of commercial regulatory approval for our Maestro?? System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our preliminary findings from our EMPOWER??? and ReCharge pivotal studies; our ability to comply with the Nasdaq continued
|
